Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Slightly overvalued vs peers
Modest margins and returns
Risk / Profitability
Risk: High
Profitability: Modest
Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Slightly overvalued vs peers
Modest margins and returns
$ 5.78
About
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that...
About
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's...
